Advanced Therapies for Ocular Diseases
Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies
Get to know us.
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.
Latest News
-
Aurion Biotech Announces Completion of Enrollment In Phase 1 / 2 Clinical Trial
Read More -
Aurion Biotech To Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (Ascrs) Annual Meeting
Read More -
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
Read More